Literature DB >> 24400237

Procalcitonin as an indicator of urosepsis.

Koichi Sugimoto1, Shogo Adomi1, Hiroyuki Koike1, Atsunobu Esa1.   

Abstract

BACKGROUND: Procalcitonin has been advocated as a marker of bacterial infection, so this study was carried out to determine the usefulness of serum procalcitonin in the early diagnosis of urosepsis.
METHODS: The subjects were 37 febrile patients with urinary tract infection in whom we examined the serum procalcitonin concentration at the start of treatment.
RESULTS: Thirty patients had acute pyelonephritis (16 simple, 14 complex), one had emphysematous pyelonephritis, five had acute prostatitis, and one had acute epididymitis. The procalcitonin level was <0.5 ng/mL in 18 patients, ≥0.5 ng/mL in one patient, ≥2 ng/mL in seven patients, and ≥10 ng/mL in 11 patients. Five of the 11 patients with procalcitonin levels ≥ 10 ng/mL had disseminated intravascular coagulation. All patients with urinary tract obstruction and disseminated intravascular coagulation had procalcitonin levels ≥ 10 ng/mL.
CONCLUSION: Although this retrospective study comprised a small number of patients, we found that procalcitonin was a useful marker for urinary tract infection.

Entities:  

Keywords:  procalcitonin; urinary tract infection; urology; urosepsis

Year:  2013        PMID: 24400237      PMCID: PMC3826854          DOI: 10.2147/RRU.S42711

Source DB:  PubMed          Journal:  Res Rep Urol        ISSN: 2253-2447


Introduction

Blood culture is a very specific method for detection and confirmation of septicemia, but test results are available only after 24 hours. C-reactive protein is an acute-phase protein produced by the liver in response to issue injury or infection. However, the C-reactive protein level can also be very high in nonseptic states, eg, postoperatively and in inflammatory disease.1,2 However, a definite correlation between infection and changes in C-reactive protein has not been documented as yet. Procalcitonin is a 13 kDa, 116-amino acid prohormone of calcitonin. In 1993, Assicot et al3 reported increased procalcitonin levels in patients with sepsis and infection. Further clinical studies indicated that bacterial inflammation and sepsis, but not viral infections or autoimmune disorders, could induce high concentrations of serum procalcitonin.3–7 In this study, we evaluated the relationship between urosepsis and procalcitonin.

Materials and methods

From January 2008 to October 2010, 37 patients with febrile urinary tract infection (UTI) had their procalcitonin levels measured and were evaluated for the severity of UTI at our hospital. Our criteria for UTI were febrile symptoms (ie, dysuria, low back pain) and a core body temperature more than 38°C. All patients provided a urine sample for culture before treatment with antibiotics. If patients needed to be hospitalized, blood culture was performed at least twice before administration of antibiotics. Blood culture was confirmed to be positive if the same organism was found in urine culture. The BRAHMS PCT-Q (Thermo Fisher Scientific, Waltham, MA, USA) is an immunochromatographic test for semiquantitative detection of procalcitonin, and is used for diagnosing and monitoring the effects of treatment for severe bacterial infection and sepsis. The BRAHMS PCT-Q test system requires an incubation period of only 30 minutes, is not apparatus-dependent, and does not need calibrating. The test uses a monoclonal mouse anticatacalcin antibody conjugated with colloidal gold and a polyclonal sheep calcitonin antibody. A procalcitonin level < 0.5 ng/mL indicates the possibility of local bacterial infection; ≥0.5 ng/mL indicates that a systemic infection (sepsis) is unlikely; ≥2 ng/mL suggests the possibility of a systemic infection (sepsis), although various other conditions are also known to induce procalcitonin; and ≥10 ng/mL indicates the likelihood of sepsis, unless other causes for a high procalcitonin level are known. It is important to note that a systemic inflammatory response is almost exclusively due to severe bacterial sepsis or septic shock.8 Comparisons between groups were performed using the Mann–Whitney U test and Kruskal–Wallis nonparametric analysis of variance.

Results

Thirty patients had acute pyelonephritis (16 without and 14 with resistant-organ acute pyelonephritis), one had emphysematous pyelonephritis, five had acute prostatitis, and one patient had acute epididymitis. The procalcitonin level was <0.5 ng/mL in 18 patients, ≥0.5 ng/mL in one patient, ≥2 ng/mL in seven patients, and ≥10 ng/mL in 11 patients. All patients had positive urine cultures. The principal bacterium was Escherichia coli (Table 1). As shown in Table 2, 16 of 20 patients had a positive blood culture, and the procalcitonin level was <0.5 ng/mL in 2/5 patients (40%), ≥2 ng/mL in 6/6 patients (100%), and ≥10 ng/mL in 8/9 patients (88.9%). There was only one patient with procalcitonin ≥ 0.5 ng/mL, so we excluded this case from the statistical analysis.
Table 1

Results of urine culture

BacteriaNumber
Escherichia coli18
Enterococcus faecalis4
Pseudomonas aeruginosa2
Klebsiella oxytoca2
Klebsiella pneumoniae2
Enterobacter cloacae2
Methicillin-resistant Staphylococcus aureus2
Staphylocossus aureus2
Proteus mirabilis1
Acinetobactor lwoffii1
Escherichia coli, ESBL-producing1
Table 2

Relationship between procalcitonin levels and positive blood culture rate

PCT levelsTotal numberNumber of blood culture-positiveRate
PCT < 0.5 ng/mL5240%
PCT ≥ 0.5 ng/mL
PCT ≥ 2 ng/mL66100%
PCT ≥ 10 ng/mL9888.9%
No significant differences were observed between procalcitonin and C-reactive proteins levels or between procalcitonin and white blood cell levels. Eleven patients had procalcitonin levels ≥ 10 ng/mL. Eight of these patients required drainage and five had disseminated intravascular coagulation. All patients with urinary tract obstruction and disseminated intravascular coagulation had procalcitonin levels ≥ 10 ng/mL (Table 3).
Table 3

Patients with procalcitonin levels ≥ 10 ng/mL

AgeSexDiseaseStoneDrainageDMhSteroidDIC
Case 172FaAPNc(+)(−)(−)(+)(−)
Case 263FAPN(+)D-Je(−)(−)(+)
Case 375FAPN(+)D-J(+)(−)(+)
Case 480FAPN(+)PNSf(+)(−)(+)
Case 573FAPN(+)D-J(−)(+)(−)
Case 637FAPN(+)D-J(−)(+)(+)
Case 758FEPNd(−)NpXg(−)(−)(−)
Case 866FAPN(−)(−)(+)(+)(−)
Case 966FAPN(+)D-J(+)(−)(+)
Case 1038FAPN(+)D-J(+)(−)(−)
Case 1192MbAPN(+)(−)(−)(−)(−)

Notes:

Female;

male;

acute pyelonephritis;

emphysematous pyelonephritis;

Double J catheter;

percutaneous nephrostomy;

nephrectomy;

diabetes mellitus.

Discussion

UTI is a disease commonly encountered in the clinical setting, and sepsis resulting from UTI is a serious condition that can affect the prognosis. It has been reported that the mortality rate due to urosepsis is 16.1%.9 It has also been reported that 78% of cases of urosepsis are due to urinary tract obstruction.10 C-reactive protein is generally regarded as a useful marker for the diagnosis of sepsis and is used along with blood culture. However, such methods are sometimes inadequate for diagnosing sepsis, and a testing method enabling more rapid and efficient diagnosis has long been considered necessary. Procalcitonin is considered a useful marker for rapid differential diagnosis of bacterial sepsis and evaluation of its severity.11–13 In a report comparing blood culture and procalcitonin, diagnostic sensitivity was 42.6% for blood culture and 70.2% for procalcitonin, and the diagnostic accuracy of procalcitonin calculated from its sensitivity and specificity was 75.4%.11 In this study, the sensitivity and specificity calculated for procalcitonin was 78%, indicating very high diagnostic efficiency. The recommended treatment for urosepsis is drainage of the obstructed urinary tract to secure its patency and removal of an infected lesion if present. Any delay in appropriate treatment can be fatal. The results of this study show that all 11 patients with a procalcitonin level ≥ 10 ng/mL had severe bacterial urosepsis. Of these patients, five also had disseminated intravascular coagulation and eight needed relief of an obstructed urinary tract. With regard to pathogenic micro-organisms, others have found no significant difference in procalcitonin levels between Gram-positive cocci and Gram-negative rods.11,13 Similar results were noted in our patients. The superior usefulness of procalcitonin levels in the diagnosis of sepsis in comparison with C-reactive protein has been previously reported.14,15 Our findings further confirm that the procalcitonin level is a useful parameter on which to base a treatment strategy because it allows prompt diagnosis of urosepsis without the need to wait for the results of blood culture. Consequently, procalcitonin should be used as an adjunctive marker to aid in the diagnosis.
  15 in total

Review 1.  Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis.

Authors:  Benjamin M P Tang; Guy D Eslick; Jonathan C Craig; Anthony S McLean
Journal:  Lancet Infect Dis       Date:  2007-03       Impact factor: 25.071

Review 2.  Therapeutic challenges of urosepsis.

Authors:  F M E Wagenlehner; A Pilatz; K G Naber; W Weidner
Journal:  Eur J Clin Invest       Date:  2008-10       Impact factor: 4.686

3.  Procalcitonin in pediatrics for differentiation of bacterial and viral infections.

Authors:  D Gendrel; C Bohuon
Journal:  Intensive Care Med       Date:  2000-03       Impact factor: 17.440

4.  Multicenter prospective study of procalcitonin as an indicator of sepsis.

Authors:  Naoki Aikawa; Seitaro Fujishima; Shigeatu Endo; Isao Sekine; Kazuhiro Kogawa; Yasuhiro Yamamoto; Shigeki Kushimoto; Hidekazu Yukioka; Noboru Kato; Kyoichi Totsuka; Ken Kikuchi; Toshiaki Ikeda; Kazumi Ikeda; Kazuaki Harada; Shinji Satomura
Journal:  J Infect Chemother       Date:  2005-06       Impact factor: 2.211

5.  Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit.

Authors:  B Müller; K L Becker; H Schächinger; P R Rickenbacher; P R Huber; W Zimmerli; R Ritz
Journal:  Crit Care Med       Date:  2000-04       Impact factor: 7.598

6.  Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs. viral infections.

Authors:  D Gendrel; J Raymond; J Coste; F Moulin; M Lorrot; S Guérin; S Ravilly; H Lefèvre; C Royer; C Lacombe; P Palmer; C Bohuon
Journal:  Pediatr Infect Dis J       Date:  1999-10       Impact factor: 2.129

Review 7.  Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis.

Authors:  Bernard Uzzan; Régis Cohen; Patrick Nicolas; Michel Cucherat; Gérard-Yves Perret
Journal:  Crit Care Med       Date:  2006-07       Impact factor: 7.598

8.  Evaluation of seminal plasma parameters in patients with chronic prostatitis or leukocytospermia.

Authors:  M Ludwig; C Kümmel; I Schroeder-Printzen; R H Ringert; W Weidner
Journal:  Andrologia       Date:  1998       Impact factor: 2.775

Review 9.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine.

Authors:  R C Bone; R A Balk; F B Cerra; R P Dellinger; A M Fein; W A Knaus; R M Schein; W J Sibbald
Journal:  Chest       Date:  1992-06       Impact factor: 9.410

10.  Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes?

Authors:  I Delèvaux; M André; M Colombier; E Albuisson; F Meylheuc; R-J Bègue; J-C Piette; O Aumaître
Journal:  Ann Rheum Dis       Date:  2003-04       Impact factor: 19.103

View more
  10 in total

1.  Reduced utility of early procalcitonin and blood culture determination in patients with febrile urinary tract infections in the emergency department.

Authors:  Marcello Covino; Alberto Manno; Giuseppe Merra; Benedetta Simeoni; Andrea Piccioni; Luigi Carbone; Evelina Forte; Veronica Ojetti; Francesco Franceschi; Rita Murri
Journal:  Intern Emerg Med       Date:  2019-10-24       Impact factor: 3.397

2.  Risk factors for concomitant positive midstream urine culture in patients presenting with symptomatic ureterolithiasis.

Authors:  Nico C Grossmann; Victor M Schuettfort; Christian D Fankhauser; Benedikt Kranzbühler; Jeannine Betschart; Anton S Becker; Thomas Hermanns; Etienne X Keller
Journal:  Urolithiasis       Date:  2022-04-20       Impact factor: 3.436

3.  Procalcitonin as a useful marker to decide upon intervention for urinary tract infection.

Authors:  Koichi Sugimoto; Nobutaka Shimizu; Naoki Matsumura; Takashi Oki; Kazuhiro Nose; Tsukasa Nishioka; Hirotsugu Uemura
Journal:  Infect Drug Resist       Date:  2013-08-07       Impact factor: 4.003

4.  The Use of Serum Procalcitonin in the Setting of Infected Ureteral Stones: A Prospective Observational Study.

Authors:  Edward Capoccia; Patrick Whelan; Benjamin Sherer; Pete Tsambarlis; Wei Phin Tan; Alexander Chow; Michael Ryan Farrell; Brijesh Patel; Shaan Setia; Brittany M Wilson; Yanyu Zhang; Dimitri Papagiannopoulos
Journal:  J Endourol       Date:  2020-11-05       Impact factor: 2.619

5.  Procalcitonin is a strong predictor of urine culture results in patients with obstructing ureteral stones: A prospective, pilot study.

Authors:  Dimitri Papagiannopoulos; Patrick Whelan; Waseem Ahmad; James Rybak; Bala Hota; Leslie Deane; Ajay Nehra
Journal:  Urol Ann       Date:  2016 Jul-Sep

6.  Diagnostic Accuracy of Procalcitonin for Predicting Blood Culture Results in Patients With Suspected Bloodstream Infection: An Observational Study of 35,343 Consecutive Patients (A STROBE-Compliant Article).

Authors:  Abderrahim Oussalah; Janina Ferrand; Pierre Filhine-Tresarrieu; Nejla Aissa; Isabelle Aimone-Gastin; Fares Namour; Matthieu Garcia; Alain Lozniewski; Jean-Louis Guéant
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.889

7.  Prognosis Risk of Urosepsis in Critical Care Medicine: A Prospective Observational Study.

Authors:  Xin-Hua Qiang; Tie-Ou Yu; Yi-Nan Li; Li-Xin Zhou
Journal:  Biomed Res Int       Date:  2016-02-03       Impact factor: 3.411

Review 8.  Prevention and management of urosepsis triggered by ureteroscopy.

Authors:  Kymora B Scotland; Dirk Lange
Journal:  Res Rep Urol       Date:  2018-07-05

9.  The procalcitonin/albumin ratio as an early diagnostic predictor in discriminating urosepsis from patients with febrile urinary tract infection.

Authors:  Xin Luo; Xiang Yang; Jiexian Li; Ge Zou; Yufeng Lin; Guoqiang Qing; Ruilin Yang; Weixiang Yao; Xuying Ye
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

10.  A systematic review on COVID-19: urological manifestations, viral RNA detection and special considerations in urological conditions.

Authors:  Vinson Wai-Shun Chan; Peter Ka-Fung Chiu; Chi-Hang Yee; Yuhong Yuan; Chi-Fai Ng; Jeremy Yuen-Chun Teoh
Journal:  World J Urol       Date:  2020-05-27       Impact factor: 4.226

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.